HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Amylyx Pharma, maintaining a price target of $8.
October 18, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Amylyx Pharma, maintaining a price target of $8.
The reiteration of a Buy rating and maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100